BiotechTube

KW-3357

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Disseminated Intravascular Coagulation (DIC)

Conditions

Disseminated Intravascular Coagulation (DIC)

Trial Timeline

Dec 1, 2011 → Apr 1, 2013

NCT ID
NCT01384396

About KW-3357

KW-3357 is a phase 3 stage product being developed by Kyowa Kirin for Disseminated Intravascular Coagulation (DIC). The current trial status is completed. This product is registered under clinical trial identifier NCT01384396. Target conditions include Disseminated Intravascular Coagulation (DIC).

What happened to similar drugs?

0 of 3 similar drugs in Disseminated Intravascular Coagulation (DIC) were approved

Approved (0) Terminated (1) Active (2)
❌KW-3357Kyowa KirinPhase 3
🔄KW-3357 + Plasma-derived antithrombinKyowa KirinPhase 3
🔄Single high dose of liposomal amphotericin B + L-AmB standard doseGilead SciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01384409Phase 3Terminated
NCT01384396Phase 3Completed
NCT00938288Phase 1Completed

Competing Products

5 competing products in Disseminated Intravascular Coagulation (DIC)

See all competitors
ProductCompanyStageHype Score
KW-3357Kyowa KirinPhase 3
32
KW-3357 + Plasma-derived antithrombinKyowa KirinPhase 3
40
Single high dose of liposomal amphotericin B + L-AmB standard doseGilead SciencesPhase 3
47
BAY 3389934 + Matching Placebo / DiluentBayerPhase 1
33
Flucytosine and fluconazole + FluconazoleBausch HealthPhase 2
21